Cipla Q3 net up 25.5 percent, slightly misses estimates
MUMBAI (Reuters) - Cipla Ltd (CIPL.NS), India's fifth largest drugmaker by sales, reported a 25.5 percent rise in quarterly profit on robust sales but slightly missed street estimates as taxes surged.
The Mumbai-based drugmaker said, net profit grew to 3.39 billion rupees in October-December from 2.7 billion rupees a year earlier. Analysts on an average had expected a net profit of 3.48 billion rupees, according to Thomson Reuters I/B/E/S.
Sales rose 18.65 percent to 20.3 billion rupees, it said.
Shares in Cipla fell 0.56 percent to 405 rupees on Wednesday when the Mumbai market closed down 0.1 percent. (Reporting by Kaustubh Kulkarni; Editing by Anand Basu)
- Tweet this
- Share this
- Digg this
- Putin says Russia not isolated over Ukraine, blames West for frosty ties
- India approves $2.6 bln mounted gun purchase - official
- Suicide bomber kills 45 at volleyball match in Afghanistan
- Pope declares sainthood of two Indians, four Italians
- China building South China Sea island big enough for airstrip - report
India approved on Saturday the purchase of 814 mounted gun systems for the army at a cost of 157.5 billion rupees ($2.55 billion), a defence ministry spokesman said. Full Article